European Journal of Cancer Prevention · 2023 · 11 citations · 14 references
MedicineOncologyBreast OncologyChemotherapyMolecular OncologyAdjuvant TherapyBreast Cancer OncologyBreast PathologyHer2-positive Breast CancerBreast Cancer Molecular SubtypesBreast Cancer PrognosisClinicopathological CorrelationCox RegressionHer2 ExpressionHer2 Gene AmplificationKaplan-meier Confidence IntervalsNeoadjuvant Chemoradiotherapy
PURPOSE: HER2-low breast cancer (BC) has renewed interests of researchers worldwide. Here, we aimed to investigate the clinicopathological characteristics of patients with HER2-low, HER2-0 and HER2 ultra-low BC and make conclusion. METHODS: We collected cases of patients who were diagnosed as BC at Jingling General hospital. Immunohistochemistry was used to redefine HER2 scores. Kaplan-Meier methods and Cox proportional hazards regression analysis were used to compare survival. RESULTS: We found that HER2-low BC was more frequent in hormone receptor (HR)-positive BC patients and was associated with fewer T3-T4, lower breast conserving surgery rate and higher adjuvant chemotherapy rate. HER2-low BC patients had better overall survival (OS) compared to HER2-0 BC in premenopausal and stage II BC. Furthermore, HER2-0 BC patients had lower Ki-67 expression levels compared to HER2-ultra low and HER2-low BC in HR-negative BC. HER2-0 BC patients also had worse OS rate compared to those with HER2-ultra low BC in HR-positive BC. Finally, HER2-0 BC patients showed a higher pathological response rate compared to those with HER2-low BC after neoadjuvant chemotherapy. CONCLUSIONS: These findings suggest that HER2-low BC has distinct biology and clinical features compared to HER2-0 BC, and more investigation is needed to understand the biology of HER2-ultra low BC.
14
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2022 · 18.2K citations · Full text
Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Journal of Clinical Oncology · 2006 · 4.5K citations · Full text
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Archives of Pathology & Laboratory Medicine · 2007 · 1.9K citations
Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Archives of Pathology & Laboratory Medicine · 2018 · 1.5K citations · Full text